Modality
Radioligand
MOA
PD-1i
Target
CD20
Pathway
Tau
HCCPompeHS
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
~Sep 2017
→ ~Dec 2018
Phase 2
~Mar 2019
→ ~Jun 2020
Phase 3
~Sep 2020
→ ~Dec 2021
NDA/BLA
Mar 2022
→ Aug 2029
NDA/BLACurrent
NCT04027060
1,518 pts·HS
2022-04→2025-02·Not yet recruiting
NCT08129934
1,907 pts·HS
2022-03→2029-08·Completed
3,425 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-02-021.2y agoPh3 Readout· HS
2029-08-143.4y awayPh3 Readout· HS
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
NDA/BLA
Complet…
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2025-02-02 · 1.2y ago
HS
Ph3 Readout
2029-08-14 · 3.4y away
HS
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04027060 | NDA/BLA | HS | Not yet recr... | 1518 | 6MWD |
| NCT08129934 | NDA/BLA | HS | Completed | 1907 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| AKR-4818 | Akero | Approved | CD20 |